DDrare: Database of Drug Development for Rare Diseases

269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群
［臨床試験数：20，薬物数：26（DrugBank：10），標的遺伝子数：12，標的パスウェイ数：90］

Searched query = "Pyogenic arthritis", "Pyoderma gangrenosum", "Acne syndrome", "PAPA syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = APD334; Adalimumab; CICLOSPORIN; Canakinumab; Ciclosporin; Cosentyx; Cosentyx®; EU/1/14/980/002; EU/1/14/980/003; Gelatin; Gevokizumab; Gevokizumab open-label; Humira; IFX-1; Infliximab; Ixekizumab; Neoral Oral Solution; Neoral soft gelatin capsules; PREDNISOLONE; Prednisolone; Secukinumab; Secukinumab 150 mg (2 injections per dose; Stelara; USTEKINUMAB; Ustekinumab; Xilonix

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03971643 (ClinicalTrials.gov)	May 16, 2019	28/5/2019	Exploratory Study of IFX-1 in Subjects With Pyoderma Gangrenosum	Open Label Exploratory Phase 2a Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Subjects With Pyoderma Gangrenosum (Optima)	Pyoderma Gangrenosum	Drug: IFX-1	InflaRx GmbH	Innovaderm Research Inc.	Recruiting	18 Years	N/A	All	18	Phase 2	United States;Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03971643
(ClinicalTrials.gov)

May 16, 2019

28/5/2019

Exploratory Study of IFX-1 in Subjects With Pyoderma Gangrenosum

Open Label Exploratory Phase 2a Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Subjects With Pyoderma Gangrenosum (Optima)

Pyoderma Gangrenosum

Drug: IFX-1

InflaRx GmbH

Innovaderm Research Inc.

Recruiting

18 Years

N/A

All

Phase 2

United States;Canada